



+

[illegible]

Examiner Signature	/Scott Long/	Date Considered	06/21/2006
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+

DT15 Rec'd PCT/FTO 14 JUL 2004

PTO/SB/08A (10-01)


Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			Application Number		
			Filing Date		
			First Named Inventor	Victor Willem Van Beusechem	
			Art Unit		
			Examiner Name		
Sheet	1	of	2	Attorney Docket Number	253-9

[illegible]

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code 3 - Number 4 - Kind Code 5 (if known)			
	SI <sub>1</sub>	WO 98/46781	10-22-1998	Genzyme Corporation	
		WO 95/12660	5-11-1995	BROAD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM	
		WO 98/01563	1-15-1998	Branton et al.	
		WO 98/46779	10-22-1998	Genzyme Corporation	
		WO 97/30732	8-28-1997	Onyx Pharmaceuticals, Inc.	
		WO 01/74403 A1	10-11-2001	Christopher B. Wood	
		WO 01/44280 A2	6-21-2001	Genovo, Inc.	
		WO 01/05437 A2	1-25-2001	Introgen Therapeutics, Inc.	
		WO 00/29573	5-25-2000	Canij, Inc.	
		WO 00/71078 A2	11-30-2000	Transgene	

Examiner Signature	/Scott Long/	Date Considered	06/21/2006
-----------------------	--------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

English language translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

10/501407

DT15 R PCT/PTO 14 JUL 2004

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	
		Filing Date	
		First Named Inventor	Victor Willem Van Beusechem
		Group Art Unit	
		Examiner Name	
Sheet 2 of 2	Attorney Docket Number	253-9	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
SL		QUERIDO E. et al., Accumulation of P53 Induced by the Adenovirus E1A Protein Requires Regions Involved in the Stimulation of DNS Synthesis, Journal of Virology, The American Society for Microbiology, US, Vol 71, No. 5, May 1997, Pages 3526-3533	
		P. YEW, X. LIU, A. BERK, Adenovirus E1B Oncoprotein Tethers a Transcriptional Repression Domain to p53, Genes and Development, Cold Spring Harbor, NY, US, Vol.8 No. 2, 1994, Pages 190-202	
		TEODORO J G et al, Adenovirus E1A Proteins induce apoptosis by Both P53-dependent and P53-independent mechanisms, Oncogene, Basingstoke, Hants, GB, Vol 11, No. 3, August 3, 1995, pages 467-474	
		QUERIDO et al., Regulation of P53 Levels by the E1B 55- Kilodalton protein and E4orf6 in Adenovirus-Infected Cells, Journal of Virology, the American Society for Microbiology, US, Vol. 71, No. 5, May 1, 1997, pages 3788-3798	
		TSUNODA H. et al., Effects of Wild-Type and Mutated P53 and ID Proteins on the Induction of Apoptosis by Adenovirus E1A, c-Myc, Bax and Nip3 in p53 Null Mouse Cerebellum Cells, Biochemical and Biophysical Research Communications Academic Press Inc. Orlando, FL, US Vol. 255, No. 3, 1999, Pages 722-730	
		BEUSECHEM et al., Conditionally Replicative Adenovirus Expressing p53 Exhibits Enhanced Oncolytic Potency, Cancer Research, Vol 62, Pages 6165-6171, November 1, 2002	

Examiner Signature	/Scott Long/	Date Considered	06/21/2006
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.